◆英語タイトル:Ankylosing Spondylitis - Global Market Outlook (2019 -2027)
◆発行会社(リサーチ会社):Stratistics MRC
Single UserUSD4,150 ⇒換算¥473,100見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥855,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Stratistics MRC社の概要はこちらでご確認いただけます。


According to Stratistics MRC, the Global Ankylosing Spondylitis Market is accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027 growing at a CAGR of 10.3% during the forecast period. Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease. Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth. However, the huge cost of treatment and lack of skilled surgeons and physiotherapists are hampering the market growth.

Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a kind of arthritis, in which spine bones grow or fuse together, causing the spine to turn into rigid. Symptoms of ankylosing spondylitis comprise pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.

Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it’s a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults. Humira can help to reduce the back pain, stiffness of AS, low cost and high efficiency.

By geography, North America is going to have a lucrative growth during the forecast period due to the more prevalence of the disease and amplified adoption of ankylosing spondylitis treatment options in the region. In addition, technological developments are driving ankylosing spondylitis treatment in this region.

Some of the key players profiled in the Ankylosing Spondylitis Market include Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc, Merck & Co, Novartis AG, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB, Inc.

Molecule Types Covered:
• Biologics
• Biosimilars
• Small Molecules

Route of Administrations Covered:
• Oral
• Parenteral

Dosage Forms Covered:
• Liquid
• Solid

Drugs Covered:
• Cimzia
• Cosentyx
• Enbrel
• Humira
• Remicade
• Simponi

Drug Types Covered:
• Anti-Inflammatory Drugs
• COX Inhibitors
• Disease-Modifying Anitrheumatic Drugs (DMARDs)
• Immunosuppressive Drugs
• JAK Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Steroids
• TNF Inhibitors
• IL-17 Inhibitors

Treatment Types Covered:
• Medication
• Surgery
• Therapy

Applications Covered:
• Adults
• Juveniles

End Users Covered:
• Hospital
• Care Home
• Clinic

Regions Covered:
• North America
• Europe
Rest of Europe
• Asia Pacific
New Zealand
South Korea
Rest of Asia Pacific
• South America
Rest of South America
• Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019 2020, 2024, and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client’s interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Ankylosing Spondylitis Market, By Molecule Type
5.1 Introduction
5.2 Biologics
5.3 Biosimilars
5.4 Small Molecules
6 Global Ankylosing Spondylitis Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Parenteral
7 Global Ankylosing Spondylitis Market, By Dosage Form
7.1 Introduction
7.2 Liquid
7.3 Solid
8 Global Ankylosing Spondylitis Market, By Drug
8.1 Introduction
8.2 Cimzia
8.3 Cosentyx
8.4 Enbrel
8.5 Humira
8.6 Remicade
8.7 Simponi
9 Global Ankylosing Spondylitis Market, By Drug Type
9.1 Introduction
9.2 Anti-Inflammatory Drugs
9.3 COX Inhibitors
9.4 Disease-Modifying Anitrheumatic Drugs (DMARDs)
9.5 Immunosuppressive Drugs
9.6 JAK Inhibitors
9.7 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9.8 Steroids
9.9 TNF Inhibitors
9.10 IL-17 Inhibitors
10 Global Ankylosing Spondylitis Market, By Treatment Type
10.1 Introduction
10.2 Medication
10.3 Surgery
10.4 Therapy
11 Global Ankylosing Spondylitis Market, By Application
11.1 Introduction
11.2 Adults
11.3 Juveniles
12 Global Ankylosing Spondylitis Market, By End User
12.1 Introduction
12.2 Hospital
12.3 Care Home
12.4 Clinic
13 Global Ankylosing Spondylitis Market, By Geography
13.1 Introduction
13.2 North America
13.2.1 US
13.2.2 Canada
13.2.3 Mexico
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 Italy
13.3.4 France
13.3.5 Spain
13.3.6 Rest of Europe
13.4 Asia Pacific
13.4.1 Japan
13.4.2 China
13.4.3 India
13.4.4 Australia
13.4.5 New Zealand
13.4.6 South Korea
13.4.7 Rest of Asia Pacific
13.5 South America
13.5.1 Argentina
13.5.2 Brazil
13.5.3 Chile
13.5.4 Rest of South America
13.6 Middle East & Africa
13.6.1 Saudi Arabia
13.6.2 UAE
13.6.3 Qatar
13.6.4 South Africa
13.6.5 Rest of Middle East & Africa
14 Key Developments
14.1 Agreements, Partnerships, Collaborations and Joint Ventures
14.2 Acquisitions & Mergers
14.3 New Product Launch
14.4 Expansions
14.5 Other Key Strategies
15 Company Profiling
15.1 Abbvie
15.2 Amgen
15.3 Boehringer Ingelheim
15.4 Bristol-Myers Squibb
15.5 Celgene
15.6 Celltrion
15.7 Eisai
15.8 Eli Lilly and Company
15.9 F. Hoffmann-La Roche
15.10 Janssen Pharmaceuticals
15.11 Johnson & Johnson Services, Inc
15.12 Merck & Co
15.13 Novartis AG
15.14 Pfizer
15.15 Regeneron Pharmaceuticals
15.16 Sanofi
15.17 Shanghai Pharmaceuticals
15.18 UCB, Inc